PIPERACILLIN AND TAZOBACTAM FOR INJECTION POWDER FOR SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)

から入手可能:

STERIMAX INC

ATCコード:

J01CR05

INN（国際名）:

PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

投薬量:

2.00G; 0.25G

医薬品形態:

POWDER FOR SOLUTION

構図:

PIPERACILLIN (PIPERACILLIN SODIUM) 2.00G; TAZOBACTAM (TAZOBACTAM SODIUM) 0.25G

投与経路:

INTRAVENOUS

パッケージ内のユニット:

10

処方タイプ:

Prescription

治療領域:

EXTENDED-SPECTRUM PENICILLINS

製品概要:

Active ingredient group (AIG) number: 0225919004; AHFS:

認証ステータス:

APPROVED

承認日:

2011-02-24

製品の特徴

_ _
_Piperacillin and Tazobactam for Injection _
_Page 1 of 47_
PRODUCT MONOGRAPH
INCUDING PATIENT MEDICATION INFORMATION
PR
PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Piperacillin Sodium/Tazobactam Sodium
Lyophilized Powder for Injection
For Intravenous Use Only
MANUFACTURER’S STANDARD
PIPERACILLIN 2 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 0.25 G (AS
TAZOBACTAM SODIUM) PER VIAL
PIPERACILLIN 3 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 0.375 G (AS
TAZOBACTAM SODIUM) PER VIAL
PIPERACILLIN 4 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 0.5 G (AS
TAZOBACTAM SODIUM) PER VIAL
PIPERACILLIN 12 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 1.5 G (AS
TAZOBACTAM SODIUM) PER VIAL
PIPERACILLIN 36 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 4.5 G (AS
TAZOBACTAM SODIUM) PER VIAL
Antibiotic/ß-lactamase Inhibitor
SteriMax Inc.
2770 Portland Drive
Oakville, ON L6H 6R4
Date of Revision:
May 10, 2018
Submission Control No: 191213
_ _
_Piperacillin and Tazobactam for Injection _
_Page 2 of 47_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
.....